Welcome to our dedicated page for Arvinas news (Ticker: ARVN), a resource for investors and traders seeking the latest updates and insights on Arvinas stock.
Arvinas, Inc. (ARVN) is a clinical-stage biopharmaceutical leader pioneering targeted protein degradation through its PROTAC® technology. This news hub provides investors and researchers with essential updates on therapeutic developments, strategic collaborations, and clinical milestones.
Access authoritative reporting on ARVN's oncology and neurodegenerative disease programs, including estrogen receptor degraders for breast cancer and novel neurological candidates. Our curated news collection features:
• Clinical trial developments
• Research collaborations
• Regulatory milestones
• Scientific presentations
Bookmark this page for real-time updates on ARVN's progress in addressing previously undruggable targets through innovative protein degradation approaches. Verify information directly through official company communications and SEC filings.
Arvinas (NASDAQ: ARVN) reported 3Q2025 results and a corporate update highlighting clinical and preclinical progress, collaboration milestones, and financial positions. Key clinical highlights include ARV-102 showing >90% PBMC LRRK2 reduction and >50% CSF reduction with brain penetration, and ARV-102 effects on distal CSF biomarkers; ARV-806 preclinical potency ~25x–40x versus competitors with >90% degradation for 7 days in models; ARV-027 demonstrated 40–60% muscle polyQ-AR reduction and functional benefit in SBMA mice. Regulatory/commercial: FDA accepted the NDA for vepdegestrant with a PDUFA date of June 5, 2026 and Arvinas/Pfizer will jointly select a commercialization partner. Cash was $787.6M at Sept 30, 2025, funding operations into H2 2028 per management.
Arvinas (NASDAQ: ARVN) will present preclinical data for its PROTAC BCL6 degrader ARV-393 in combination with glofitamab at the 2025 American Society of Hematology (ASH) Annual Meeting.
The poster (Publication No. 1520) is in Session 605: Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I, on December 6, 2025, 5:30 PM–7:30 PM ET, at OCCC – West Halls B3–B4. The full abstract is available via the ASH online program.
Arvinas (Nasdaq: ARVN) said management will participate in two investor conferences in November 2025: Guggenheim’s 2nd Annual Healthcare Innovation Conference on Tuesday, November 11, 2025 and the Jefferies London Healthcare Conference on Tuesday, November 18, 2025.
Both presentations will offer a live audio webcast accessible via links and the company’s Events and Presentations web section.
Arvinas (Nasdaq: ARVN) will report third quarter 2025 financial results and provide a corporate update during a live webcast on Wednesday, November 5, 2025 at 8:00 a.m. ET.
Management will review the company's Q3 2025 financial results and deliver a corporate update. The live webcast is accessible under “Events and Presentations” on Arvinas' investor website and a replay will be available at www.arvinas.com after the event.
Arvinas (Nasdaq: ARVN) announced preclinical data for ARV-806, a PROTAC KRAS G12D degrader, presented Oct 24, 2025 at the AACR-NCI-EORTC conference.
Key points: picomolar in vitro KRAS G12D degradation across pancreatic, colorectal and lung lines; >25-fold greater antiproliferative potency versus clinical-stage G12D inhibitors; >40-fold higher KRAS G12D degradation potency versus a clinical-stage G12D degrader; single IV dose produced >90% KRAS G12D degradation for seven days with c-MYC suppression and BIM induction for ≥5 days; ≥30% tumor volume reductions in pancreatic, colorectal CDX and a lung PDX model. ARV-806 is in a Phase 1 trial (NCT07023731).
Arvinas (Nasdaq: ARVN) will present preclinical data for ARV-806, a PROTAC KRAS G12D degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.
The data will be shown as Poster B107 in Poster Session B on October 24, 2025 from 12:30–4:00 PM ET. The full abstract is available in the conference online program.
Arvinas (NASDAQ: ARVN) reported patient-reported outcomes from the Phase 3 VERITAC-2 trial showing vepdegestrant delayed deterioration in overall quality of life, pain, and multiple functioning domains versus fulvestrant in patients with ESR1-mutated ER+/HER2- advanced or metastatic breast cancer previously treated with endocrine-based therapy.
The trial enrolled 624 patients (270 with ESR1 mutations) across 213 sites in 25 countries; progression-free survival showed a statistically significant improvement and overall survival remains the key secondary endpoint.
Arvinas (Nasdaq: ARVN) will present new clinical data for vepdegestrant at the ESMO Congress, Oct 17–21, 2025 in Berlin.
Highlights include Phase 3 VERITAC-2 patient-reported outcomes comparing vepdegestrant (VEP) vs fulvestrant (FUL) in ESR1-mutated ER+/HER2− advanced/metastatic breast cancer, presented by Dr. Mario Campone on Oct 20, 2025 at 11:25 CEST (Presentation 489MO, mini oral). Also scheduled is TACTIVE-N, a Phase 2 neoadjuvant study of vepdegestrant vs anastrozole in postmenopausal localized ER+/HER2− breast cancer, presented by Dr. Peter A. Fasching on Oct 19, 2025 at 10:40 CEST (Presentation 293MO, mini oral).
Both abstracts are available in the ESMO online program.
Arvinas (Nasdaq: ARVN) announced late‑breaking Phase 1 data for ARV-102, an oral brain‑penetrant PROTAC LRRK2 degrader, presented at MDS 2025 on Oct 5, 2025.
The PR states ARV-102 was generally well tolerated (single doses up to 200 mg; multiple daily doses up to 80 mg) with no discontinuations or SAEs. Plasma and CSF exposure increased dose‑dependently, indicating brain penetration. The PR reports >90% PBMC LRRK2 reductions at ≥20 mg and median PBMC reductions of 86% (50 mg) and 97% (200 mg) in patients. In healthy volunteers, 14 days of 80 mg produced CSF proteomic decreases in lysosomal and microglial pathway markers linked to Parkinson’s disease.
Arvinas (NASDAQ:ARVN) announced two upcoming presentations featuring clinical data for ARV-102, their investigational PROTAC degrader targeting LRRK2 for Parkinson's disease, at the 2025 International Congress of Parkinson's Disease and Movement Disorders® in Honolulu.
The presentations include a first-in-human study examining safety, pharmacokinetics, and pharmacodynamics of ARV-102 in healthy participants, and a late-breaker presentation on pathway engagement in both healthy volunteers and Parkinson's disease patients. The sessions are scheduled for October 7-8, 2025.
FAQ
What is the current stock price of Arvinas (ARVN)?
What is the market cap of Arvinas (ARVN)?
